FARESTON TABLETS 60MG

EUEMA:by INN L02BA02(WHO) 2-[4-[(1Z)-4-Chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy]-N,N-dimethylethanamine 89778-26-7Y89778-27-8 (citrate) 3005573 4325 DB00539Y 2275722Y 7NFE54O27T D08620Y CHEBI:9635Y ChEMBL1655Y T0R (PDBe,RCSB PDB) DTXSID3023689 Interactive image ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3 InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-YKey:XFCLJVABOIYOMF-QPLCGJKRSA-NY Toremifene, sold und‍‍‍‍‍‍​​​‍​​​​​​er the brand nameFarestonamong others, is a medication which is used in the treatment ofadvanced breast cancerinpostmenopausalwomen.It is takenby mouth. Side effectsof toremifene includehot flashes,sweating,nausea,vomiting,dizziness,vaginal discharge, andvaginal bleeding.It can also causeblood clots,irregular heartbeat,cataracts,visual disturbances,elevated liver enzymes,endometrial hyperplasia, andendometrial cancer.High blood calcium levelscan occur in women withbone metastases. The medication is aselective estrogen receptor modulator(SERM) and hence is a mixedagonist–antagonistof theestrogen receptor(ER), thebiological targetofestrogenslikeestradiol.It hasestrogeniceffects inbone, theliver, and theuterusandantiestrogeniceffects in thebreasts.It is atriphenylethylenederivativeand is closely related totamoxifen. Toremifene was introduced for medical use in 1997.It was the firstantiestrogento be introduced since tamoxifen in 1978.It is available as ageneric medicationin theUnited States.